These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19174400)

  • 1. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.
    Do DV; Nguyen QD; Shah SM; Browning DJ; Haller JA; Chu K; Yang K; Cedarbaum JM; Vitti RL; Ingerman A; Campochiaro PA
    Br J Ophthalmol; 2009 Feb; 93(2):144-9. PubMed ID: 19174400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
    Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
    Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
    Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
    Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
    Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
    Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS;
    Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
    Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
    Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
    Nguyen QD; Tatlipinar S; Shah SM; Haller JA; Quinlan E; Sung J; Zimmer-Galler I; Do DV; Campochiaro PA
    Am J Ophthalmol; 2006 Dec; 142(6):961-9. PubMed ID: 17046701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.
    Chun DW; Heier JS; Topping TM; Duker JS; Bankert JM
    Ophthalmology; 2006 Oct; 113(10):1706-12. PubMed ID: 17011952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study.
    Velez-Montoya R; Fromow-Guerra J; Burgos O; Landers MB; Morales-Catón V; Quiroz-Mercado H
    Retina; 2009 Jan; 29(1):20-6. PubMed ID: 18784623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
    Boyer DS; Faber D; Gupta S; Patel SS; Tabandeh H; Li XY; Liu CC; Lou J; Whitcup SM;
    Retina; 2011 May; 31(5):915-23. PubMed ID: 21487341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study.
    Grenga P; Lupo S; Domanico D; Vingolo EM
    Retina; 2008 Oct; 28(9):1270-5. PubMed ID: 18664938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
    Nguyen QD; Shah SM; Browning DJ; Hudson H; Sonkin P; Hariprasad SM; Kaiser P; Slakter JS; Haller J; Do DV; Mieler WF; Chu K; Yang K; Ingerman A; Vitti RL; Berliner AJ; Cedarbaum JM; Campochiaro PA
    Ophthalmology; 2009 Nov; 116(11):2141-8.e1. PubMed ID: 19700196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.
    Dugel PU; Blumenkranz MS; Haller JA; Williams GA; Solley WA; Kleinman DM; Naor J
    Ophthalmology; 2012 Jan; 119(1):124-31. PubMed ID: 22115710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
    Heier JS; Boyer D; Nguyen QD; Marcus D; Roth DB; Yancopoulos G; Stahl N; Ingerman A; Vitti R; Berliner AJ; Yang K; Brown DM;
    Ophthalmology; 2011 Jun; 118(6):1098-106. PubMed ID: 21640258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
    Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
    Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.